PRODUCT CODE: M1701-5

HLA-DR Mouse Monoclonal Antibody [10-D8] (M1701-5)

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.
  • Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.
  • Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human skin tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
  • Flow cytometric analysis of Daudi cells with HLA-DR antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

HLA-DR Mouse Monoclonal Antibody [10-D8] (M1701-5)

Immunogen

Peptide

Host

Mouse

Positive Control

Raji, human tonsil tissue, human lung cancer tissue, human colon cancer tissue, human kidney tissue, human skin tissue, Daudi.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

10-D8

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Peptide affinity purified

MOLECULAR WEIGHT

29 kDa

Isotype

IgG1

APPLICATION DILUTION

  • WB

  • 1:500-1:1,000

  • IHC-P

  • 1:50-1:200

  • FC

  • 1:50-1:200

TARGET

UNIPROT #

PROTEIN NAME

HLA-DR

SYNONYMS

DR alpha chain antibody; DR alpha chain precursor antibody; DRA_HUMAN antibody; DRB1 antibody; DRB4 antibody; Histocompatibility antigen HLA DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody

SEQUENCE SIMILARITIES

Belongs to the MHC class II family.

POST-TRANSLATIONAL MODIFICATION

Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.

SUBCELLULAR LOCATION

Cell membrane. Endoplasmic reticulum membrane. 

FUNCTION

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in mhc ii-a/b dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.